Nanovesicles have emerged as a promising drug delivery system
for enhancing the bioavailability and therapeutic potential of various
pharmacological agents, particularly those targeting the central nervous
system. Cannabidiol, a non-psychoactive cannabinoid, has demonstrated
neuroprotective, anti-inflammatory, and anticonvulsant properties, making it
a promising candidate for treating neurological disorders such as epilepsy,
multiple sclerosis, and neurodegenerative diseases. However, its therapeutic
efficacy is often limited by poor solubility, rapid metabolism, and difficulty in
crossing the blood-brain barrier. The development of cannabidiol-loaded
nanovesicles aims to overcome these limitations by improving drug stability,
enhancing transport across biological barriers, and providing sustained
release within the central nervous system.
Share this article
Journal of Nephrology & Therapeutics received 784 citations as per Google Scholar report
